Literature DB >> 21798780

Adherence to treatment in multiple sclerosis.

R Santolaya Perrín1, M Fernández-Pacheco García Valdecasas, L Arteche Eguizabal, I Gema Pérez Pérez, N Muñoz Muñoz, O Ibarra Barrueta, G Callejón Callejón.   

Abstract

OBJECTIVE: To find out if patients with multiple sclerosis adhere to treatment with beta interferons and glatiramer acetate, the percentage of withdrawal and its causes.
METHODS: Observational, longitudinal, prospective, national, multicentre study which selected multiple sclerosis patients who attended the hospital pharmacy department to collect their medication. The main variable was the adherence percentage during a year, measured as the relationship between the dose of the dispensed and necessary drug. Treatment withdrawals and their causes were then measured.
RESULTS: Over a six-month period, 543 patients from 39 pharmacy departments were included. The average time exposed to the drugs during the study period was 312 days and the average adherence in this period was 61.5% (95% CI: 59.4-63.5). Thirty-four (6.26%) of the 543 study participants withdrew treatment, which for most cases was decided by the doctor.
CONCLUSIONS: Multiple sclerosis patients' treatment adherence during a period of one year has been lower than the ideal. The causes should therefore be analysed and corrective measures established.
Copyright © 2010 SEFH. Published by Elsevier Espana. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21798780     DOI: 10.1016/j.farma.2011.02.006

Source DB:  PubMed          Journal:  Farm Hosp        ISSN: 1130-6343


  2 in total

1.  Persistence and adherence to interferon and glatiramer acetate in patients with multiple sclerosis.

Authors:  Emma Bartolomé-García; Ángela Usarralde-Pérez; Patricia Sanmartín-Fenollera; Monserrat Pérez-Encinas
Journal:  Eur J Hosp Pharm       Date:  2017-08-31

2.  Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by Rebismart® in patients with multiple sclerosis.

Authors:  María Dolores Edo Solsona; Emilio Monte Boquet; Bonaventura Casanova Estruch; José Luis Poveda Andrés
Journal:  Patient Prefer Adherence       Date:  2017-03-02       Impact factor: 2.711

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.